PEAR-MET

Indication: Metastatic triple-negative breast cancer

Location: United Kingdom (see below for sites)

Type: Observational

Protocol (please note, this may not be upto date, and should not be used by trial sites)

Background:

Triple negative breast cancer (TNBC) is a type of breast cancer that lacks receptors for oestrogen and progesterone hormones and the HER2 protein. Once the disease has spread (metastasised) it is generally treated with a range of systemic therapies, such as chemotherapy and immunotherapy.

Different patients may respond to different treatments, but at the moment there is no way of predicting who will respond to which drugs.

Description:

This observational study is recruiting up to 30 patients with metastatic or locally advanced TNBC that are due to start a new line of treatment. Patients will need to undergo an additional procedure to remove a small piece of tumour using a core needle biopsy. This tumour will be used for analysis on Pear’s system to determine the likelihood of response to a given chemotherapy regimen. As this is an observational study, the results will not be shared with your oncologist at the time of initial treatment, and you will be treated using the standard of care. The goal of the study is to establish the accuracy of Pear’s test at predicting response to treatment to help guide future patients to better treatments.

If you are interested in enrolling, please contact your doctor about whether you are eligible.

For more information, contact trials@pearbio.com

Open Sites & Investigators:

Guys’ and St. Thomas’ Hospital (Lead Site): Dr. Sheeba Irshad

Bart’s Hospital, London: Dr. Peter Hall

Imperial College Healthcare NHS Trust: Dr. Suzy Cleator